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ABSTRACT
Background: To reduce deaths from asthma, further use of inhaled corticosteroids (ICS) in accordance with
the guidelines is required. The present study was conducted because specialists are responsible for increasing
the use of guidelines, but the current state of asthma care provided by specialists in primary clinical settings
has not been clarified.
Methods: In collaboration with five primary medical facilities throughout Japan, severity of asthma, contents of
asthma therapy, and the implementation rate of pulmonary function testing and peak flow measurements were
analyzed for 1007 outpatients40 years old with stable bronchial asthma. In all patients, peak inspiratory flow
(PIF) was measured during examination.
Results: Either ICS or ICSlong-acting beta 2 agonist (LABA) was used in almost all patients with at least mild
persistent asthma. Although treatments adhered to the guidelines, therapeutic steps did not match asthma se-
verity in many patients with mild intermittent asthma. Large gaps existed between facilities that measure pulmo-
nary function and PEF in daily clinical practice and those that do not. While mean PIF value for all subjects was
well maintained at 102.0 ± 29.1 Lmin, some patients may not have been able to inhale efficiently in terms of
PIF (5.1% of TurbuhalerⓇ users and 5.7% of DiskhalerⓇ users).
Conclusions: When stepping down asthma therapy, some confusion in policy may exist, leading to guideline
mismatches. Differences in the implementation of pulmonary function and PEF measurements, as indicators
for long-term management, need to be minimized among specialists. For maintaining effective inhalation, inspi-
ratory flow should be periodically checked.
KEY WORDS
asthma, inhaled corticosteroid (ICS), peak expiratory flow (PEF), peak inspiratory flow (PIF), pulmonary func-
tion test
INTRODUCTION
Chronic eosinophilic inflammation of the airway is
the main pathological feature of bronchial asthma. To
prevent the progression of irreversible airway remod-
eling, inflammation needs to be controlled early.1 At
present, inhaled corticosteroids (ICSs) represent the
most effective therapeutic method for controlling in-
flammation, and major treatment guidelines, such as
those published by the Japanese Society of Allergol-
ogy, recommend active usage as the main therapeutic
agent in asthma therapy.2,3 However, use of ICSs in
Japan cannot be considered sufficient. According to
the Asthma Insights and Reality in Japan (AIR-J)
study, a telephone survey conducted by Adachi et al.
in 2000 and then 5 years later in 2005, the usage rate
of ICSs in adults increased from 12% to 18%, but this
number was clearly lower than the 20% in Europe
(Asthma Insights and Reality in Europe in 1999 [AIR-
E]).4 To improve this situation and further promote
ICS usage, widespread adoption of standard therapy
based on the guidelines must be promoted in primary
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Table 1 Patients characteristics
1007Numbers of patients
393/614Gender (Male/Female)
59.6 ± 12.6Mean age (year)
Severity of asthma N (%)
52 (5.2)Mild intermitent
290 (28.2)Moderate intermitent
466 (46.3)Moderate persistent
184 (18.3)Severe persistent
15 (1.5)Unknown
10.3 ± 12.7Duration of asthma (months)
42.5 (%)<5 yr
19.7 (%)5 - 10 yr
10.5 (%)10-15 yr
 7.3 (%)15-20 yr
 3.6 (%)20-25 yr
12.7 (%)25< yr
Smoking status (%)
 78 (7.7) Present smoker
279 (27.7)Ex-smoker
636 (63.2)Never smoker
 14 (1.4) Unknown
Co-morbid conditions (%)
40.3None
28.8Alergic rhinitis
18.2Hypertension
10.9Hypercholesterolemia
 7.1Diabetes melitus
 4.5Osteoporosis
each of them <3.0 (%)Others
clinical settings. Specialists belonging to the Japanese
Society of Allergology provide care in general clinical
settings, but no studies to date have investigated how
these specialists provide such care and the current
state of care provided by specialists remains yet to be
elucidated. To promote the guidelines, it is very im-
portant: to know how specialists involved in primary
care provide care according to the guidelines in rou-
tine clinical settings; to ascertain differences between
actual clinical settings and the contents of guideline-
based therapy; and to identify factors that prevent or
limit the spread of guideline-based therapy.
Issues related to inhalation devices comprise
patient-related factors preventing greater use of ICSs.
Which device is selected markedly affects how effi-
ciently an inhalant is inhaled. Two types of ICS de-
vices are used: pressurized metered-dose inhalers
(pMDIs); and dry-powder inhalers (DPIs). When
physicians prescribe an ICS, the type of inhalation de-
vice is selected almost simultaneously. DPIs include
fluticasone (commercial name: FlutideⓇ, hereinafter
referred to as FP) and fluticasonesalmeterol (com-
mercial name: AdvairⓇ), and DiskusⓇ is the main in-
halation device. Fluticasone can be inhaled using
DiskhalerⓇ in a pMDI form. TurbuhalerⓇ is a but-
esonide device. With DPIs, inspiratory effort is re-
quired by the patient, and low inspiratory flow makes
it impossible for some patients to inhale even with ef-
fort, causing some individuals to be unable to com-
pletely inhale the prescribed dose.5 However, how
many patients maintain sufficient inspiratory flow in
actual clinical settings is unclear, and the current
state is unclear as few reports have examined this
subject. Furthermore, bidirectional switching be-
tween DPIs and pMDIs often occurs in daily clinical
practice, and investigation of to what degree patient
inspiratory flow is maintained is necessary to ensure
that no problems with inspiratory flow are present.
In this study, the actual condition of asthma ther-
apy was surveyed with the cooperation of specialists
belonging to the Japanese Society of Allergology,
who are very familiar with the guidelines and who are
active in primary clinical settings throughout Japan.
In all patients, peak inspiratory flow (PIF) was meas-
ured to ascertain whether appropriate devices were
being selected in terms of inhalation.
METHODS
STUDY SUBJECTS AND PERIOD
Subjects comprised consenting patients 40 years
old with stable bronchial asthma who had been
treated on an outpatient basis at one of the five medi-
cal facilities below over a 6-month period from Sep-
tember 2008 to February 2009. During examination,
patients were confirmed to have not experienced ex-
acerbated symptoms or asthmatic attacks for at least
the last 3 months. The present survey was conducted
on pure asthma patients by excluding asthma patients
complicated by clear chronic obstructive pulmonary
disease (COPD). The clinical significance and pur-
pose of the study and the possible disadvantages of
participation in the study were explained in detail to
each patient before their enrollment in the study and
a written informed consent was obtained. Personal in-
formation was carefully handled, and data were man-
aged using initials and numbers so that individuals
could not be identified. The present study was con-
ducted based on the ethical regulations specified by
the Declaration of Helsinki (as revised in Seoul
2008).
PARTICIPATING FACILITIES (FIVE SITES)
This study was performed by the cooperation of spe-
cialists in the following facilities who belong to the
Japanese Society of Allergology.
Miyatake Clinic (Osaka), Oki Clinic (Tokyo), Oh-
michi Respiratory Clinic (Hokkaido), Hiroshima Al-
lergy and Respiratory Disease Clinic (Hiroshima) and
Department of Internal Medicine at JA Tohno-Kousei
Hospital (Gifu).
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Table 2 Relationships between usage medications (%) and severity of asthma and age range
UnknownOthersAnti-Cho
SABA
inhalation
LABA
patch
LABA
inhalationTheoLTRA
ICS/
LABAICSNSeverity
2.25.41.5 9.810.413.420.635.7 †33.162.51007Total patients
Severity of asthma
7.71.90.0 9.630.8 † 1.915.4 9.6 7.744.2  52Mild intermitent
2.86.60.0 5.5 7.2 9.3 7.922.1 †11.483.4 290Moderate intermitent
1.94.11.1 5.812.415.521.936.9 †40.657.9 466Moderate persistent
0.58.24.927.2 5.417.938.062.5 †55.445.1 184Severe persistent
Age range
2.14.00.511.2 5.910.713.136.4 †39.657.0 374<55 yr
1.58.21.511.9 9.713.020.136.8 †31.667.3 26956-64 yr
4.04.00.9 8.512.517.423.236.6 †29.962.9 22465-74 yr
0.75.75.0 4.320.715.037.130.7 †23.667.1 14075< yr
† The 2nd usage medications next to ICS or ICS/LABA in each range.
ICS, inhaled corticosteroid; LABA, long-acting beta2-adrenergic agonists; LTRA, leukotriene receptor antagonist; Theo, Theophyline; 
SABA, short-acting long-acting beta2-adrenergic agonists.
Table 3 Performance rates of each examinations
Performance rate (%)
Faculty
ACTPulmonaryfunction test
Measurement of
PEF
Number of
patients
 0.0 1.0 1.5194A
 0.014.7 0.0232B
 0.099.0 0.3290C
16.891.0 8.5131D
67.588.287.6160E
Fig. 1 Usage rates of DPIs and p-MDIs according to age 
range.
77.2
69.9
65.9
17.5
8.9
18.5
24.3
29.4
4.2
5.8
4.8
5.3
6.5
86.9
75.0
0% 20% 40% 60% 80% 100%
Total
(n = 952)
<55yr
(n = 360)  
55-64 yr
(n = 260)
65-74 yr
(n = 206)
75yr<
(n = 126)
DPI p-MDI unknown
INVESTIGATED ITEMS
In all patients, the current severity of asthma was as-
sessed according to the Asthma Prevention and Man-
agement Guidelines in Japan (JGL2006), based on
current symptoms and administered drugs. Further-
more, disease duration, smoking status and complica-
tions were investigated. Implementation status and
the results of pulmonary function tests and asthma
control tests (ACTs)6 performed in the last 6 months
were examined. When peak expiratory flow (PEF)
was being measured as part of routine management,
these values were also analyzed. PEF was measured
3 times using a Peak Flowmeter MiniLightⓇ (Clem-
ent Clarke International Limited, Essex, UK), and the
maximum value was used for analysis. To ascertain
whether patients maintained sufficient inspiratory
flow and whether devices capable of efficient inspira-
tion were selected, inspiratory flow was measured in
all patients. Inspiratory flow was measured using In-
checkⓇ (Clement Clarke International Limited) with
an adaptor reflecting discusⓇ resistance. Each patient
was asked to perform maximum voluntary inspiration
3 times, and the largest value of the 3 measurements
was used as PIF.
STATISTICAL ANALYSIS
Statistical values were expressed as mean ± standard
deviation, with the level of significance set at 5%. An
unpaired t test was used to compare PIF values be-
tween men and women. Multiple linear regression
analysis was used for examining correlations between
PIF values and other indices (Fig. 3). These statisti-
cal analyses were conducted using Excel version 4.0
software (Microsoft Co., USA).
RESULTS
During the study period, 1007 patients40 years old
with stable asthma consented to participate in the
present study.
CURRENT STATE OF ASTHMA PATIENTS
Table 1 shows the characteristics of all patients.
Among facilities that participated in the present
Ohbayashi H et al.
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Fig. 2 Distributions of PIF values in (A) total patients, (B) male/female groups, and (C) each ICS usage group.
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study, about 75% of patients had mild-moderate per-
sistent asthma, and about 20% had severe asthma,
whereas only about 5% had mild intermittent asthma.
Of the total, 40.3% did not have complications and had
only asthma. Since patients complicated by COPD
were excluded from the present study, the most com-
mon complication other than COPD was allergic
rhinitis (28.8%), followed by hypertension, hyperlipi-
demia and diabetes, in that order, and showing that
complication with lifestyle diseases was common.
Among the present total patient population, mean du-
ration of asthma was 10.3 ± 12.7 years.
Table 2 shows the usage rate of drugs, including
ICSs. In almost all patients with at least mild persis-
tent asthma, either ICS or ICS + LABA was adminis-
tered. Mismatches were found between the severity
of asthma before starting the JGL2006 guideline treat-
ment and currently administered drugs in the step of
mild intermittent asthma. ICSs were administered to
44.2% of patients with mild intermittent asthma. On
the other hand, four patients with mild intermittent
asthma (7.7%) were using ICS + LABA, which was not
in accordance with the JGL2006. Among the 30.8% of
patients with mild intermittent asthma who used
LABA patch, nine patients were using only LABA
patch. Another four patients with mild intermittent
asthma used more than two drugs among ICS, LTRA,
theophylline and LABA patch. Irrespective of sever-
Asthma Therapy by Allergists in Japan
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Fig. 3 Corelations between PIF values and: A) age; B) body mass index (BMI); C) PEF values; D) FEV1.0 values; and E) 
ACT scores.
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ity, leukotriene receptor antagonist (LTRA) was pref-
erentially coadministered with either ICS or ICS +
LABA. The usage rate of currently prescribed drugs
was analyzed in relation to age, and irrespective of
age, either ICS or ICS + LABA was prescribed to
most patients, with LTRA frequently used as a con-
current drug (Table 2). Figure 1 shows the usage
rate of each ICS type, i.e. DPI or pMDI, in all age
groups. Older patients tended to show greater use of
pMDIs, suggesting that primary physicians tend to
select a device by taking into account age-related de-
creases in inspiratory flow. No notable tendency ex-
isted in the use of DPI or pMDI in relation to severity
of asthma (no data shown).
IMPLEMENTATION RATE OF PULMONARY
FUNCTION TEST, PEAK FLOW MEASUREMENT
AND ACT
Table 3 shows the implementation rate of each test
over the 6-month period at each facility. Marked dif-
ferences were identified in the implementation rate of
tests in daily clinical practice among the facilities. In
particular, facilities could be divided into both ex-
tremes of those that almost routinely conducted pul-
monary function tests, and others that rarely con-
ducted pulmonary function tests. Except for one facil-
ity, PEF was not routinely measured. This reflects the
current situation in which routine testing is difficult in
busy primary clinical settings.
PIF
Among the total patient population, mean PIF was
102.0 ± 29.1 Lmin. The results of PIF values accord-
ing to the severity of asthma (Step of asthma) were
89.5 +- 27.8 (Lmin) (Step I, n = 52), 105.04 +- 28.9
(Lmin) (Step II, n = 290), 102.1 +- 28.8 (Lmin)
(Step II, n = 464), and 99.4 +- 30.1 (Lmin) (Step IV,
n = 183). There was no statistical significance among
the above four groups. Figure 2A shows the distribu-
tion among patients. PIF was 30 Lmin for only 4
patients (0.4%), and these 4 patients had severe per-
sistent asthma. Figure 2B shows the distribution of
PIF values among male and female patients. Mean
PIF was significantly higher for male patients (118.9 ±
28.6 Lmin) than for female patients (91.1 ± 23.8 L
min; p < 0.001). When comparing PIF in relation to
ICS agent forms, mean PIF was 103.7 ± 28.0 Lmin
for DPI patients and 96.4 ± 31.4 Lmin for pMDI pa-
tients (p = 0.006), showing a tendency toward pMDI
usage in patients with low PIF values. Figure 2C
Ohbayashi H et al.
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shows the distribution of PIF values for each ICS.
CORRELATION BETWEEN PIF AND EACH INDI-
CATOR
Figure 3A-E shows the correlation of PIF values to
age, body mass index (BMI), PEF, forced expiratory
volume during 1 second (FEV1.0) and ACT scores.
PIF exhibited a significant negative correlation to age
and a significant positive correlation to PEF, FEV1.0
and ACT score.
DISCUSSION
In the present study, with the cooperation of five al-
lergists who were very familiar with the guidelines
and were involved in primary care throughout Japan,
we investigated the current state of primary asthma
therapy provided by specialists. About 75% of patients
examined had mild to moderate persistent asthma,
and about 20% had severe asthma. This shows the
current state of patients visiting allergists in primary
clinical settings. The usage rate of ICS or ICSLABA
was very high, and ICSs were actively prescribed in
accordance with the guidelines. The present study
examined care provided by only five specialists, not
all specialists in the Society, but we believe that the
present results are unlikely to differ widely from the
therapeutic content of the current primary care pro-
vided by other specialists in Japanese primary clinical
settings. This study clarified three characteristics.
First, particularly among patients with mild inter-
mittent asthma, therapeutic steps as viewed from cur-
rently prescribed drugs did not match the severity of
asthma as indicated by primary physicians in many
cases. In the present patient group, patients with sta-
ble asthma who had no symptoms within routine
long-term management were selected, and steps (dis-
ease stages) ascertained based on asthma symptoms
were “step 1” in most patients (mild intermittent
asthma), with a small ratio of step-2 patients (mild
persistent asthma). According to JGL2006, a single
agent (low-dose ICS, LTRA or theophylline) should
be used in patients with mild intermittent asthma. For
patients in the present study with mild intermittent
asthma, the sum of ICS, LTRA and theophylline us-
age rates was about 70% (Table 2). However, four pa-
tients with mild intermittent asthma (7.7%) used ICS
LABA. And another nine patients were using only
LABA patch. Four patients also used more than two
drugs among ICS, LTRA, theophylline and LABA
patch. Those patients were not treated in accordance
with the JGL2006. In the present study, the usage
rate of LABA patch was particularly high in patients
with mild intermittent asthma, as LABA patches are
easy to use. Furthermore, according to the Sal-
meterol Multi-Center Asthma Research Trial con-
ducted in the United States, the incidence of adverse
reactions in patients on LABA monotherapy was sig-
nificantly high among African Americans,7 and al-
though specialists avoid LABA monotherapy, since
there have not been reports of severe reactions with
LABA patch, the risk for LABA monotherapy in
asthma may not be well recognized. However, we be-
lieve that there are bigger reasons why standard ther-
apy is not being followed. After the diagnosis of
asthma, guideline-based therapy is performed for a
certain period of time, and almost all patients eventu-
ally improve to a stable asymptomatic state. It has
been reported in recent years that, by performing
guideline-based therapy, therapy compliance im-
proves to significantly reduce symptoms, subse-
quently significantly reducing ICS use and the associ-
ated medical costs.8 Although the guidelines mention
stepping down after achieving an asymptomatic sta-
ble state for 3 months, some degree of confusion
remains about the step down in actual clinical set-
tings due to the fear of attack and exacerbation.
When a state is achieved in which step down is possi-
ble, some physicians reduce or discontinue ICS in
about 3 months in accordance with the guidelines,
while others continue to administer ICS for a longer
period of time. The underlying reason for this is that
the guidelines do not clearly state which clinical indi-
cators should be used for a step down or the ration-
ales for indicators and timing. As a result, particularly
in mild intermittent patients, confusion in the primary
clinical setting causes a mismatch between severity
and actual therapy.
Second, some facilities routinely measure pulmo-
nary function and peak flow in daily clinical practice,
but some facilities did not measure these at all during
the 6 months, and marked differences existed in the
rate of implementation (Table 3). The convenience
and usefulness of ACT for controlling asthma has
been recognized, but marked differences exist in the
implementation rate among facilities, and this test
cannot be said to be sufficiently conducted in daily
clinical practice. When therapy is initiated based on
the guidelines, pulmonary function findings, PEF val-
ues and ACT scores are also used as control indica-
tors as symptoms improve. Most patients subse-
quently reach an asymptomatic stable state. In this
stable state, PEF values and pulmonary function pa-
rameters mainly reflecting the central airway, such as
FEV1.0, reach a plateau. As a result, in very busy pri-
mary clinical settings, the necessity of continuous
measurements is emphasized less, lowering the rate
of implementation.
Third, in the present study, PIF was measured in
all subjects. Even among patients examined by spe-
cialists, appropriate devices were not being selected
based on PIF in some patients. As specialists, meas-
uring PIF in daily clinical practice and selecting more
appropriate devices is even more important. For
Diskus users, if PIF is within a range of 30-90 Lmin,
the volume of drug inhalation can be maintained in a
stable manner mostly irrespective of PIF values.9 In
Asthma Therapy by Allergists in Japan
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the present study, the number of patients with PIF
<30 Lmin in whom DPI inhalation was considered
difficult was unexpectedly low (n = 4, 0.4%), suggest-
ing that DiskusⓇ can be used in almost all patients.
Also, bidirectional switching between DPIs and
pMDIs often occurs in daily clinical practice, but
DiskusⓇ users do not need to make a switch to a
pMDI based solely on inspiratory flow. In particular,
pMDIs tended to be preferred over DPIs in older pa-
tients (Fig. 1), but from a perspective of inspiratory
flow, DiskusⓇ users do not need to make a switch to
a pMDI. With TurbuhalerⓇ, drug inhalation is consid-
ered possible with PIF 30 Lmin,10 but various
studies have reported that PIF 60 Lmin is re-
quired to efficiently deliver budesonide particles into
the lung.11,12 The present study used the Diskus
adaptor, and since device resistance is greater for
TurbuhalerⓇ than for DiskusⓇ, some TurbuhalerⓇ
users with PIF <60 Lmin (5.1%) may not be inhaling
efficiently (Fig. 2C). In the same manner, for Disk-
halerⓇ users with PIF <60 Lmin (5.7%), the amount
of residual powder following inhalation is high,5 dem-
onstrating a lack of effective inhalation. With both
DiskusⓇ and TurbuhalerⓇ, once PIF values exceed
90 Lmin, deposition in the throat increases, hinder-
ing efficient inhalation.13 However, inspiratory flow in
the present study was measured to ensure that mini-
mum inspiratory flow was maintained. PIF was subse-
quently measured with maximum voluntary inspira-
tion. Therefore, in patients with PIF >90 Lmin, inha-
lation needs to be practiced using a device such as
InCheckⓇ to achieve the most suitable inspiratory
flow for each device. In the present study, PIF values
exhibited a significant positive correlation to PEF and
FEV1.0 (Fig. 3C, D) and a weak positive correlation
to ACT score (Fig. 3E), confirming their usefulness
as indicators of asthma control. According to Banno
et al., PIF correlates significantly to PEF, and per-
forming therapy based on PIF values reportedly re-
sulted in more appropriate patient control and better
pulmonary function.14 In this study, when we made
the study protocols, we made a decision to collect
outpatients with asthma aged 40 yo. The major
reason why we collected the data from asthmatics
aged40 years old in this study was the comparison
with the data of patients with COPD. We performed a
separate survey study concerning the PIF values of
patients with COPD, at the same time as this survey
study. In that study, the average of the PIF values
was 97.5 +- 29.6 (Lmin) (n = 175). However, the av-
erages of PIF values were shown to decrease accord-
ing to the stage of COPD; 104 +- 27.0 (Lmin) (Stage
I, n = 40), 108.5 +- 28.0 (Lmin) (Stage II, n = 58),
91.0 +- 25.9 (Lmin) (Stage III, n = 40), and 70.9 +-
23.8 (Lmin) (Stage IV, n = 22, p < 0.001 compared
with those of Stage I). On the other hand, the aver-
ages of PIF values were significantly unchanged ac-
cording to the severity of asthma (Step of asthma) in
this study. That is a major point of difference in PIF
values between the results of patients with asthma
and those of COPD.
In November 2009, the 2009 Asthma Prevention
and Management Guidelines in Japan (JGL2009)
were released.15 One major improvement in these
guidelines was that changing therapeutic steps in re-
sponse to control is outlined more clearly. Severity of
asthma and current therapeutic steps have conven-
tionally been used interchangeably, but are clearly
differentiated using expressions indicating severity,
rather than numbers 1-4. Furthermore, starting with
mild intermittent asthma, active use of ICSs as the
first choice of drug is recommended, and dose of ICS
in each step is changed from “consider use”, “low
dose”, “moderate dose” and “high dose” to “low
dose”, “low to moderate dose”, “moderate to high
dose” and “high dose” to give the range of dosages
within steps to facilitate dose adjustment. As also
shown in the present study, the new guidelines help
specialists who sufficiently prescribe ICSs to form
clearer thought processes, and mismatches between
severity and ICS usage are minimized, thus making
the guidelines more useable for clinicians in situ.
Compared to the GINA (Global Initiative for Asthma),
the new guidelines set clearer goals for achieving
more complete asymptomatic control, matching the
lofty goal of specialists who do not want anyone in Ja-
pan dying of asthma.
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